drugset / Trial / NCT01000818

A Study to Evaluate the Effect of Famotidine and Omeprazole on MK0518 (Raltegravir) Pharmacokinetics in Human Immunodeficiency Virus (HIV)-Infected Patients (0518-054)

NCT01000818

Phase 1 Completed 18 enrolled Merck Sharp & Dohme LLC
Non-randomizedSingle-groupOpen-labelTreatment

Summary

An open-label, 3-period, fixed-sequence study in a panel of 18 HIV-infected patients on MK0518 as part of a stable treatment regimen for HIV.

Timeline

Start
2008-06
Primary completion
2009-03
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Famotidine Other / unclassified 20 mg Oral
Subject Omeprazole Other / unclassified 20 mg Oral
Subject Raltegravir Other / unclassified 400 mg Oral